Aligos Therapeutics has been granted a patent for compounds of Formula I, pharmaceutical compositions containing them, and methods for treating diseases. The claim specifically mentions a compound of Formula I. GlobalData’s report on Aligos Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Aligos Therapeutics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Aligos Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Aligos Therapeutics's grant share as of February 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11858913B2) discloses a compound of Formula I, along with various derivatives and salts. The compound, along with its stereoisomers and tautomers, is characterized by specific structural features, including the formation of non-aromatic monocyclic or polycyclic rings with various substituents such as halogen, alkyl, and cycloalkyl groups. Additionally, the patent covers pharmaceutical compositions containing the disclosed compound, its derivatives, or salts, formulated with suitable excipients for therapeutic use.

Furthermore, the patent encompasses a group of specific compounds, including (R)-6-amino-2-(3,5-dichloro-4-((7-methyl-1-oxo-2,5,6,7-tetrahydro-1H-cyclopenta[d]pyridazin-4-yl)oxy)phenyl)-1,2,4-triazine-3,5(2H,4H)-dione and various other derivatives with distinct structural variations. These compounds exhibit potential pharmacological activity and can be utilized in the development of novel pharmaceutical formulations. The patent also highlights the use of specific aromatic monocyclic rings in certain derivatives, further expanding the scope of the disclosed compounds for potential therapeutic applications.

To know more about GlobalData’s detailed insights on Aligos Therapeutics, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies